Loading
A phase 2 trial of IBI363 in lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., not yet recruiting.
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07402070 by Innovent Biologics (Suzhou) Co. Ltd., with a registry enrolment figure of 10 participants, started 2026-02-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: IBI363. Conditions listed: Resectable Stage II-III Non-small Cell Lung Cancer. Primary outcome: Pathologic Complete Response (pCR) rate; Safety parameters: the incidence of Treatment-related Adverse Event, (TRAEs); Safety parameters: the incidence of treatment-emergent adverse events (TEAEs). Lung eligibility wording from the registry: "Histologically or cytologically confirmed primary NSCLC:". Sites: China. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.